Chronic Lymphocytic Leukemia Clinical Trials in Fairfax, Virginia

3 studies are recruiting for chronic lymphocytic leukemia in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

    The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib i…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Inova Schar Cancer Institute ( Site 0015), Fairfax, Virginia
    Locations
    203 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06136559 on ClinicalTrials.gov

  2. Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

    The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi)…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Virginia Cancer Specialists, Fairfax, Virginia
    Locations
    6 in total
    Run by
    Nurix Therapeutics, Inc.

    See if you can join NCT07516093 on ClinicalTrials.gov

  3. A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

    Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetocl…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Virginia Cancer Specialists - Fairfax /ID# 268155, Fairfax, Virginia
    Locations
    70 in total
    Run by
    AbbVie

    See if you can join NCT06428019 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.